Prostate-specific membrane antigen (PSMA) is an essential molecular regulator of prostate
cancer (PCa) progression coded by the FOLH1 gene. The PSMA protein has become an …

The mainstay of medical treatment has been tyrosine kinase inhibitors (TKIs) for renal cell
cancer (RCC), cytotoxic chemotherapy for urothelial cancer (UC), and androgen deprivation …

Background ARTO trial was designed to evaluate the difference in terms of outcomes
between patients affected by oligo metastatic castrate resistant prostate cancer (mCRPC) …

Simple Summary Oligometastatic prostate cancer is an intermediate stage between
localised and metastatic disease. Today, there are many advances in the diagnosis of this …

Background In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival
benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted …

The second-generation antiandrogens have achieved an ever-growing list of approvals and
indications in subsets of prostate cancer. Here, we provide an overview of second …

PURPOSE To develop a novel artificial intelligence (AI)–powered method for the prediction
of prostate cancer (PCa) early recurrence and identification of driver regions in PCa of all …

BACKGROUND: Stereotactic body radiotherapy (SBRT) is used to deliver ablative dose of
radiation to spinal metastases. OBJECTIVE: To report the first dedicated series of spine …

The phase III VISION trial using 177Lu-PSMA-617 has significant implications for the field of
theranostics and broad repercussions for the clinical management of prostate cancer …

Simple Summary Despite early utilization of new hormonal agents (NHA, ie, abiraterone,
enzalutamide and apalutamide) for combined androgen deprivation therapy (ADT) for …